PE20140161A1 - Compuesto biciclico - Google Patents

Compuesto biciclico

Info

Publication number
PE20140161A1
PE20140161A1 PE2013001328A PE2013001328A PE20140161A1 PE 20140161 A1 PE20140161 A1 PE 20140161A1 PE 2013001328 A PE2013001328 A PE 2013001328A PE 2013001328 A PE2013001328 A PE 2013001328A PE 20140161 A1 PE20140161 A1 PE 20140161A1
Authority
PE
Peru
Prior art keywords
benzoxazol
methylethyl
acetamide
oxy
optionally replaced
Prior art date
Application number
PE2013001328A
Other languages
English (en)
Inventor
Tsuneo Yasuma
Makoto Kamata
Tohru Yamashita
Hideki Hirose
Masataka Murakami
Asato Kina
Kazuko Yonemori
Ryo Mizojiri
Ikuo Fujimori
Takuya Fujimoto
Zenichi Ikeda
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20140161A1 publication Critical patent/PE20140161A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

SE REFIERE A COMPUESTOS BICICLICOS DE FORMULA (I) DONDE R1 ES -COR2, EN DONDE R2 ES N O UN ANILLO AROMATICO DE 5 O 6 MIEMBROS OPCIONALMENTE SUSTITUIDO; R3 ES ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON HALOGENO, O CICLOALQUILO(C3-C6); R4a Y R4b SON CADA UNO H, N, ENTRE OTROS; X ES O, CO, S, SO, ENTRE OTROS; A ES UN ANILLO AROMATICO DE 5 O 6 MIEMBROS OPCIONALMENTE SUSTITUIDO; P ES UN ANILLO DE 5 MIEMBROS AROMATICO O NO AROMATICO OPCIONALMENTE SUSTITUIDO; Q ES UN ANILLO AROMATICO DE 6 MIEMBROS OPCIONALMENTE SUSTITUIDO; R6 ES ALQUILO(C1-C6) O CICLOALQUILO(C3-C6). SON COMPUESTOS PREFERIDOS: N-[(1S)-2-({6-[6-(CICLOPROPILMETOXI)-1,3-BENZOXAZOL-2-IL]PIRIDIN-3-IL}OXI)-1-METILETIL]ACETAMIDA; N-[(1S)-2-({6-[6-(CICLOPROPILMETOXI)-1,3-BENZOXAZOL-2-IL]-5-FLUOROPIRIDIN-3-IL}OXI)-1-METILETIL]ACETAMIDA; N-[(1S)-2-{[6-(6-ETOXI-1,3-BENZOXAZOL-2-IL)PIRIDIN-3-IL]OXI}-1-METILETIL]ACETAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACETIL-CoA CARBOXILASA SIENDO UTILES EN EL TRATAMIENTO DE OBESIDAD, DIABETES
PE2013001328A 2010-11-30 2011-11-29 Compuesto biciclico PE20140161A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010266097 2010-11-30
JP2011175330 2011-08-10

Publications (1)

Publication Number Publication Date
PE20140161A1 true PE20140161A1 (es) 2014-02-19

Family

ID=45418740

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001328A PE20140161A1 (es) 2010-11-30 2011-11-29 Compuesto biciclico

Country Status (23)

Country Link
US (1) US8729102B2 (es)
EP (1) EP2649062B1 (es)
JP (1) JP5824517B2 (es)
KR (1) KR20140001965A (es)
CN (1) CN103347872B (es)
AR (1) AR084032A1 (es)
AU (1) AU2011337565A1 (es)
BR (1) BR112013013417A2 (es)
CA (1) CA2819400A1 (es)
CL (1) CL2013001520A1 (es)
CO (1) CO6751239A2 (es)
CR (1) CR20130281A (es)
DO (1) DOP2013000118A (es)
EA (1) EA201390794A1 (es)
EC (1) ECSP13012719A (es)
ES (1) ES2536319T3 (es)
MA (1) MA34713B1 (es)
MX (1) MX2013006113A (es)
PE (1) PE20140161A1 (es)
SG (1) SG190925A1 (es)
TW (1) TW201242951A (es)
UY (1) UY33756A (es)
WO (1) WO2012074126A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5693611B2 (ja) 2010-04-27 2015-04-01 武田薬品工業株式会社 二環性化合物
CA2853221A1 (en) 2011-10-24 2013-05-02 Tohru Yamashita Bicyclic compound
EP2928473B1 (en) * 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
PL403149A1 (pl) * 2013-03-14 2014-09-15 Celon Pharma Spółka Akcyjna Nowe związki pochodne pirazolilobenzo[d]imidazolu
US10208044B2 (en) 2013-05-10 2019-02-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
WO2014182943A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
EP2994128B1 (en) 2013-05-10 2019-01-30 Gilead Apollo, LLC Acc inhibitors and uses thereof
BR112015028152A2 (pt) * 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
CA2923884A1 (en) 2013-09-12 2015-03-19 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
EP3068788A1 (en) 2013-11-14 2016-09-21 Cadila Healthcare Limited Novel heterocyclic compounds
WO2016020295A1 (en) 2014-08-04 2016-02-11 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
CN104193731B (zh) * 2014-08-27 2017-03-15 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
HRP20211778T1 (hr) 2014-08-29 2022-03-18 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina
JP2016079168A (ja) * 2014-10-17 2016-05-16 塩野義製薬株式会社 ９員縮合環誘導体
CN104447725B (zh) * 2014-10-22 2018-02-02 浙江大学 一种手性含亚胺吡啶噁唑啉的化合物及其制备方法
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
MX2018003903A (es) * 2015-09-29 2018-09-21 Oncotherapy Science Inc Compuesto biciclico y uso del mismo para inhibicion de suv39h2.
CN105601626A (zh) * 2015-11-04 2016-05-25 浙江大学 一种含2-取代噁唑啉衍生物的制备方法
TWI744256B (zh) 2015-11-06 2021-11-01 美商英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
ES2833955T3 (es) 2016-01-05 2021-06-16 Incyte Corp Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
WO2018200517A1 (en) 2017-04-24 2018-11-01 Tesaro, Inc. Methods of manufacturing of niraparib
SG11202003428VA (en) 2017-10-18 2020-05-28 Incyte Corp Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
CR20210165A (es) 2018-09-05 2021-10-01 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3-quinasa (pi3k) campo técnico
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
EP4126874A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
WO2021198956A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
WO2023217989A1 (en) 2022-05-12 2023-11-16 Syngenta Crop Protection Ag Alkoxy heteroaryl- carboxamide or thioamide compounds
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
ATE286395T1 (de) * 1997-04-30 2005-01-15 Lilly Co Eli Antithrombotische mittel
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2001082925A1 (fr) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Antagonistes de l'hormone concentrant la melanine
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
AU2003254650B2 (en) * 2002-07-24 2010-09-09 Qlt, Inc. Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
AR041867A1 (es) 2002-11-01 2005-06-01 Takeda Pharmaceutical Agente para prevenir o tratar neuropatia
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
EP1564213A4 (en) 2002-11-22 2009-05-27 Takeda Pharmaceutical IMIDAZOLE DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
RU2006126978A (ru) 2003-12-25 2008-01-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 3-(4-бензилоксифенил)пропановой кислоты
EP1698624B1 (en) 2003-12-26 2012-06-27 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
EP2253315A1 (en) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical PHENOXYALKANSÄUREVERBINDUNG
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
RU2008108984A (ru) 2005-08-10 2009-09-20 Такеда Фармасьютикал Компани Лимитед (Jp) Терапевтический агент от диабета
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP1996567B1 (en) * 2006-02-15 2013-09-18 AbbVie Inc. Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
CN102731451B (zh) 2006-06-27 2015-07-29 武田药品工业株式会社 稠环化合物
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US8410087B2 (en) 2006-10-19 2013-04-02 Takeda Pharmaceutical Company Limited Indole compound
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
MX2009008103A (es) 2007-02-09 2009-08-18 Takeda Pharmaceutical Compuestos anulares fusionados como agonistas parciales de prar-gamma.
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
US20110301155A1 (en) 2007-06-19 2011-12-08 Tsuneo Yasuma Indazole compounds for activating glucokinase
JP5535931B2 (ja) * 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
US8927576B2 (en) * 2009-04-06 2015-01-06 PTC Therpeutics, Inc. HCV inhibitor and therapeutic agent combinations
JP5693611B2 (ja) 2010-04-27 2015-04-01 武田薬品工業株式会社 二環性化合物
WO2012108478A1 (ja) 2011-02-09 2012-08-16 武田薬品工業株式会社 単環化合物

Also Published As

Publication number Publication date
CR20130281A (es) 2013-10-07
CN103347872B (zh) 2014-12-24
US8729102B2 (en) 2014-05-20
CA2819400A1 (en) 2012-06-07
US20120142714A1 (en) 2012-06-07
WO2012074126A1 (en) 2012-06-07
TW201242951A (en) 2012-11-01
AU2011337565A1 (en) 2013-07-11
WO2012074126A9 (en) 2013-06-06
MX2013006113A (es) 2013-11-01
AR084032A1 (es) 2013-04-17
AU2011337565A2 (en) 2013-07-11
JP5824517B2 (ja) 2015-11-25
JP2013545718A (ja) 2013-12-26
CL2013001520A1 (es) 2013-10-18
UY33756A (es) 2012-06-29
CN103347872A (zh) 2013-10-09
SG190925A1 (en) 2013-07-31
EA201390794A1 (ru) 2013-11-29
ECSP13012719A (es) 2013-12-31
EP2649062A1 (en) 2013-10-16
CO6751239A2 (es) 2013-09-16
BR112013013417A2 (pt) 2019-09-24
EP2649062B1 (en) 2015-04-08
ES2536319T3 (es) 2015-05-22
KR20140001965A (ko) 2014-01-07
MA34713B1 (fr) 2013-12-03
DOP2013000118A (es) 2013-09-30

Similar Documents

Publication Publication Date Title
PE20140161A1 (es) Compuesto biciclico
PE20141308A1 (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20130279A1 (es) Compuestos heteroarilo nitrogenados
PE20170004A1 (es) Inhibidores de biaril cinasa
PE20110409A1 (es) Compuestos heterociclicos antiviricos
PE20130235A1 (es) Derivados de aminopirimidina como moduladores de la lrrk2
PE20141582A1 (es) Pirimidinas anilladas sustituidas y uso de las mismas
PE20141307A1 (es) Aril dihidropiridinona y piperidinona como inhibidores de monoacilglicerol aciltransferasa (mgat2)
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
PE20141375A1 (es) Activadores de glucoquinasa
PE20130155A1 (es) Derivados de ariletinilo
PE20170444A1 (es) Herbicidas de piperidinona
PE20130576A1 (es) Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10
DE602005023343D1 (de) Pyrimidinderivate als gpcr-agonisten
PE20141828A1 (es) 6-alquinilo piridinas como mimeticos smac
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
PE20081612A1 (es) Analogos de las pterinas
PE20141540A1 (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
PE20130405A1 (es) Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
PE20130647A1 (es) Indoles
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
PE20140623A1 (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
AR064735A1 (es) Agonistas de gpcr y composicion farmaceutica en base al compuesto

Legal Events

Date Code Title Description
FA Abandonment or withdrawal